# Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease

> **NCT03228940** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Resverlogix Corp**

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** RVX000222

## Key facts

- **NCT ID:** NCT03228940
- **Lead sponsor:** Resverlogix Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-11-22
- **Primary completion:** 2022-11-22
- **Final completion:** 2022-11-22
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Changed development priorities
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03228940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03228940, "Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03228940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*